Fisher Funds Management LTD Invests $667,000 in Waters Corporation $WAT

Fisher Funds Management LTD acquired a new position in shares of Waters Corporation (NYSE:WAT) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,239 shares of the medical instruments supplier’s stock, valued at approximately $667,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of WAT. Sky Investment Group LLC acquired a new stake in shares of Waters during the first quarter valued at about $532,000. First Community Trust NA purchased a new stake in shares of Waters in the 1st quarter valued at approximately $281,000. Kavar Capital Partners Group LLC acquired a new position in shares of Waters in the 1st quarter worth approximately $376,000. Park National Corp OH acquired a new position in shares of Waters in the 1st quarter worth approximately $949,000. Finally, E. Ohman J or Asset Management AB boosted its position in shares of Waters by 73.7% during the 1st quarter. E. Ohman J or Asset Management AB now owns 4,385 shares of the medical instruments supplier’s stock worth $1,306,000 after purchasing an additional 1,861 shares during the period. 94.01% of the stock is currently owned by hedge funds and other institutional investors.

Waters Trading Up 0.2%

NYSE WAT opened at $356.26 on Monday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79. The firm has a market cap of $34.98 billion, a price-to-earnings ratio of 45.27, a PEG ratio of 2.15 and a beta of 1.21. The firm has a 50 day simple moving average of $342.66 and a 200-day simple moving average of $348.22. Waters Corporation has a one year low of $275.05 and a one year high of $414.15.

Waters (NYSE:WAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the firm earned $2.25 EPS. The firm’s revenue for the quarter was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities research analysts anticipate that Waters Corporation will post 14.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Evercore upgraded Waters from an “in-line” rating to an “outperform” rating and set a $350.00 price target on the stock in a research note on Monday, April 6th. UBS Group raised their price target on Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a research report on Wednesday, May 6th. HSBC lifted their price objective on Waters from $415.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Waters in a report on Monday, April 20th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $394.56.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.